Impact of drug-resistant tuberculosis on the survival of HIV-infected patients

International Journal of Tuberculosis and Lung Disease

Volumn 11, Issue 3, 2007, Pages 325-330

  Sungkanuparph, Somnuek ^a   Eampokalap, B ^b   Chottanapund, S ^b   Thongyen, S ^b   Manosuthi, W ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

AIDS; Drug resistance; HIV; Survival; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; ETHAMBUTOL; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; MALE; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 33947379999     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Raviglione M C, Snider D E Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-226.
2. Corbett E L, Watt C J, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-1021.
3. Godfrey-Faussett P, Maher D, Mukadi Y D, Nunn P, Perriens J, Raviglione M. How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. Bull World Health Organ 2002; 80: 939-945.
4. Putong N, Pitisuttithum P, Supanaranond W, et al. Mycobacterium tuberculosis infection among HIV/AIDS patients in Thailand: clinical manifestations and outcomes. Southeast Asian J Trop Med Public Health 2002; 33: 346-351.
5. Lalloo U G, Amod FC. HIV-associated tuberculosis and cryptococcosis in resource-limited settings. Curr HIV/AIDS Rep 2005; 2: 116-121.
6. Corbett E L, Churchyard G J, Charalambos S, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 34: 1251-1258.
7. Quy H T, Cobelens F G, Lan N T, Buu T N, Lambregts C S, Borgdorff M W. Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2006; 10: 45-51.
8. Nelson L J, Talbot E A, Mwasekaga M J, et al. Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002. Lancet 2005; 366: 488-490.
9. Sanders M, Van Deun A, Ntakirutimana D, et al. Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey. Int J Tuberc Lung Dis 2006; 10: 178-183.
10. Vanacore P, Koehler B, Carbonara S, et al. Drug-resistant tuberculosis in HIV-infected persons: Italy 1999-2000. Infection 2004; 32: 328-332.
11. Yoshiyama T, Supawitkul S, Kunyanone N, et al. Prevalence of drug-resistant tuberculosis in an HIV endemic area in northern Thailand. Int J Tuberc Lung Dis 2001; 5: 32-39.
12. Punnotok J, Shaffer N, Naiwatanakul T, et al. Human immunodeficiency virus-related tuberculosis and primary drug resistance in Bangkok, Thailand. Int J Tuberc Lung Dis 2000; 4: 537-543.
13. Eyob G, Guebrexabher H, Lemma E, et al. Drug susceptibility of Mycobacterium tuberculosis in HIV-infected and -uninfected Ethiopians and its impact on outcome after 24 months of follow-up. Int J Tuberc Lung Dis 2004; 8: 1388-1391.
14. Toungoussova O S, Nizovtseva N I, Mariandyshev A O, Caugant D A, Sandven P, Bjune G. Impact of drug-resistant Mycobacterium tuberculosis on treatment outcome of culture-positive cases of tuberculosis in the Archangel oblast, Russia, in 1999. Eur J Clin Microbiol Infect Dis 2004; 23: 174-179.
15. Veen J, Raviglione M, Rieder H L, et al. Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J 1998; 12: 505-510.
16. Fox W, Ellard G A, Mitchison D A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3 (Suppl 2): S231-S279.
17. Eisenach K D, Sifford M D, Cave M D, Bates J H, Crawford J T. Detection of Mycobacterium tuberculosis in sputum samples using a polymerase chain reaction. Am Rev Respir Dis 1991; 144: 1160-1163.
18. Jonas V, Alden M J, Curry J I, et al. Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by amplification of rRNA. J Clin Microbiol 1993; 31: 2410-2416.
19. Jou N-T, Yoshimori R B, Mason G R, Louie J S, Liebling M R. Single-tube, nested, reverse transcriptase PCR for detection of viable Mycobacterium tuberculosis. J Clin Microbiol 1997; 35: 1161-1165.
20. Shah J S, Liu J, Buxton D, et al. Q-Beta replicase-amplified assay for detection of Mycobacterium tuberculosis directly from clinical specimens. J Clin Microbiol 1995; 33: 1435-1441.
21. Whalen C, Horsburgh CR, Jr., Hom D, Lahart C, Simberkoff M, Ellner J. Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. AIDS 1997; 11: 455-460.
22. Jon F. Tuberculosis. In: Cohen C, Powderly W G, eds. Infectious Diseases. Vol 1, 2nd ed. London, UK: Mosby, 2004: pp 401-418.
23. Dean G L, Edwards S G, Ives N J, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16: 75-83.
24. Palella F J Jr, Delaney K M, Moorman A C, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
25. Hogg R S, Heath K V, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-454.
26. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Vibhagool A. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand. J Infect 2006; 52: 188-194.
27. Breen R A, Miller R F, Gorsuch T, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 2006; 61: 791-794.
28. Weiner M, Benator D, Peloquin C A, et al., and the Tuberculosis Trials Consortium. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis 2005; 41: 1343-1349.
29. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006; 53: 357-363.